LDS/Medical Tests/Desipramine, Serum

Desipramine, Serum

Desipramine is a member of the class of drugs known as tricyclic antidepressants (TCAs). The use of TCAs first began in 1958 when imipramine use was shown to be particularly effective at treatment of melancholic depression. TCAs remained the first-line treatment for depression for approximately 30 years before the development of selective serotonin reuptake inhibitors (SSRIs); the use of antidepressants continues to be one of the primary ways to treat clinical depression. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorders, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease, or childhood enuresis.

In general, TCAs are lipophilic, have large volumes of distribution, are well absorbed, and reach peak serum concentrations within 2-12 hours. Most TCAs are metabolized by the cytochrome P450 system and many of the metabolites are biologically active. The half-lives of these particular drugs are quite variable. The half-life of desipramine is between15-24 hours. Many of the therapeutic ranges for these drugs have not been established or there is non-consensus.

The effects associated with desipramine abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.

In conclusion, desipramine and other TCAs are one of the most frequently encountered drugs of abuse due to the percentage of the population that is taking them, the frequency with which these drugs are prescribed, and their high potential for serious side effects.

  • Therapeutic monitoring in blood
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay (IA) type test indicates only the presence of TCAs and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC/MS or LC/MS.

Therapeutic concentration in blood: 100-300 ng/mL

Toxic concentration: >400 ng/mL

Fatality concentration: variable

 

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

 

Cut-Off Ranges

Cut-off values are generally used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as GC/MS or LC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), or Liquid Chromatography/Mass Spectroscopy (LC/MS). The main method of quantification is via LC/MS. This particular method of analysis can be used to detect TCAs such as desipramine. Desipramine can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is generally preferred over acid hydrolysis.

Serum (SST). 

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing, such as genotyping *CYP3A4, CYP2D6, CYP1C19,* and *CYP1A2,* which are mainly responsible for metabolism of tricyclic antidepressants, may be useful. Therefore, genotyping of these variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
  • Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):539-46. [PMID: 1183139]
  • J Clin Psychiatry. 1983 May;44(5 Pt 2):27-34. [PMID: 6343361]
  • J Iowa Med Soc. 1983 Aug;73(8):320-3. [PMID: 6355323]
  • Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
  • Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapheutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.